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Five years ago, we reported the identification and characterization of several regulatory T-cell epitopes (now called Tregitopes)
that were discovered in the heavy and light chains of IgG (De Groot et al. Blood, 2008). When added ex vivo to human PBMCs,
these Tregitopes activated regulatory T cells (Tregs), increased expression of the transcription factor FoxP3, and induced IL-
10 expression in CD4+ T cells. We have now shown that coadministration of the Tregitopes in vivo, in a number of different
murine models of autoimmune disease, can suppress immune responses to antigen in an antigen-specific manner, and that this
response is mediated by Tregs. In addition we have shown that, although these are generally promiscuous epitopes, the activity
of individual Tregitope peptides is restricted by HLA. In this brief report, we provide an overview of the effects of Tregitopes
in vivo, discuss potential applications, and suggest that Tregitopes may represent one of the “active pharmaceutical ingredients”
of IVIg. Tregitope applications may include any of the autoimmune diseases that are currently treated almost exclusively with
intravenous immunoglobulin G (IVIG), such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Multifocal
Motor Neuropathy (MMN), as well as gene therapy and allergy where Tregitopes may provide a means of inducing antigen-specific
tolerance.
1. Introduction
In recent work [1], we identified an important trigger for the
expansion and activation of regulatory T cells (Tregs), which
are T cell epitopes contained in the framework sequences
of immunoglobulin G (IgG). Further studies suggested that
these peptides were natural T regulatory cell epitopes (Tregit-
opes) thatmay explain, at least in part, the tolerance-inducing
effects of polyclonal immunoglobulin when delivered as a
therapy (intravenous immunoglobulin or IVIG). The defin-
ing characteristics of Tregitopes were that they (i) stimulated
CD4+, CD25hi, and FoxP3+ T cells; (ii) suppressed effector
T-cell responses to other antigens in suppressor assays; and
(iii) were associated with T cell IL-10 production in vivo
and in vitro [1]. Subsequently, Tregitope peptides have been
shown to replicate the effects of IVIG in mouse models of
Multiple Sclerosis (EAE), allergy, and asthma, confirming our
primary observations [2–4]. Consistent with their intrinsic
immunosuppressive property, Tregitope peptides adminis-
tered in complete or incomplete Freund’s Adjuvant (CFA or
IFA) suppress immune responses to coadministered antigens,
but are not immunogenic per se [5].
While coadministration of Tregitope peptides with target
antigen(s) effectively suppresses antigen-specific immune
responses [6], Tregitope peptides are also particularly active
in animal models on their own, if they are given during the
acute phase of inflammation. For example, upon onset of
diabetes Tregitope peptides formulated in IFA and delivered
as a single dose to NOD mice (intraperitoneally) effectively
suppressed diabetes in 58 percent of the mice for 25 weeks
[6]. In a rigorous and independent NOD study conducted
by the National Institute of Diabetes and Digestive and
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Table 1: Partial list of previously identified human IgG tregitopes.
HLA Location In vitro validation In vivo validation
Promiscuous EMX score∗ IgG Murine Human Mouse Human
Tregitope 167 Y 30.05 Fc Y Y Y In Fc
Tregitope 289 Y 22.57 Fc Y Y Y In Fc
Tregitope 084 N 14.07 Fab (N/A) Y — ∗∗
Tregitope 009 N 14.09 Fab (N/A) Y — ∗∗
Tregitope 029B N 16.38 Fab (N/A) Y Y Y
Tregitope 134 N 2.70 Fab (N/A) Y Y —
∗EMX Score: EpiMatrix-predicted MHC binding promiscuity; correlates with T-cell response.
N/A: no murine homolog.
∗∗Other data, not able to disclose.
In Fc: fc Fusion proteins have both Tregitope 167 and 289 present. See D. W. Scott publications.
Kidney Diseases (NIDDK), Tregitope peptides were the only
novel therapy of six tested that exhibited “notable trends;”
three diabetic mice remitted entirely, all of which were in
the Tregitope peptide treatment groups. None of the other
therapies tested (such as DT22669 (DiaKine), Aralast NP
(Baxter Healthcare), ISO-092 (Feinstein Institute for Medical
Research), Celastrol (Pi and Pi Technology), and PGC-
GLP-1 (PharmaINCorporation)) resulted in the prolonged
remission seen with Tregitope peptides in this aggressive
model of diabetes [7]. In addition, Tregitope peptides deliv-
ered in adeno-associated virus (AAV) ten days prior to
TNBS (2,4,6 trinitrobenzenesulfonic acid-induced colitis)
treatment were sufficient to suppress inflammatory bowel
disease (and induce immigration of Tregs to the intestine) in
this model of autoimmune disease [8].
2. Tregitopes: What Are They?
2.1. Natural and Induced Regulatory T Cells and Tolerance.
It has become increasingly clear that CD4+CD25+FoxP3+
Tregs are an important component of immune regulation [9].
Autoreactive T cells with moderate T-cell receptor affinity
may escape deletion in the thymus to circulate where they
function as “natural” regulatory T cells (nTregs) [10]. Two
distinct Treg subsets are described in the literature: natural
nTregs specific for self-epitopes and generated by high-
avidity selection in the thymus, and inducible iTregs that are
derived from conventional (CD4+, FoxP3−) T cells following
stimulation in the periphery [11, 12]. nTregs can induce the
conversion of conventional T cells to iTregs via cytokine-
dependent and -independent mechanisms, a process called
infectious tolerance [13, 14].
It has been surmised that autologous proteins contain
nTregitopes; however, few of these have beenmapped. Immu-
noglobulin G has been known to exhibit tolerogenic proper-
ties for decades, and a number of previous publications have
alluded to the potential presence of regulatory or “suppressor”
epitopes in IgG constant domains, whether located to the
constant (Fc) or binding region (Fab). For example, Baxevanis
et al. described a tolerizing effect of Ig Fc that was localized
to the CH2 region, consistent with the location of several
Tregitopes [15]; a peptide isolated from the Fab region of
an anti-idiotypic peptide (which overlaps one of the sub-
sequently identified Tregitopes) suppressed Systemic Lupus
Erythematosis in humans and in mice [16, 17]; a peptide
derived from the highly conserved J region framework was
shown by Warnke et al. to induce Tregs to expand and
suppress immune responses in suppressor assays [18].
We perform immunogenicity studies for a range of clients
in the preclinical phase ofmonoclonal antibody development
[19, 20]. Using immunoinformatics tools (EpiMatrix [21]),
now comprised in the ISPRI toolkit [20], we scanned the con-
stant domains of human IgG and found that these and other
regions of immunoglobulin G contained putative epitopes
that were predicted to bind to more than one HLA and that
were highly conserved in existing databases of IgG sequences.
We hypothesized that they would serve to induce Tregs rather
than T effector T cells, and that this might explain why some
monoclonal antibodies that contain “foreign” (not seen in
thymic development) sequences might not generate immune
responses. Whether these Tregitope peptides induce nTregs
or iTregs (peripheral, inducible Tregs), or both, remains
to be determined. Nonetheless, we note that monoclonal
antibodies that contain the full complement of Tregitopes are
less likely to trigger immune responses despite hypervariable
sequences that are comprised of de novo sequences and thus
might appear “foreign” [22].
2.2. Tregitopes Are Found in IgG and in Fab as well as in Fc.
As shown in Table 1, Tregitopes are promiscuous epitopes (as
predicted by EpiMatrix) and are located in the Fc and the Fab
regions of IgG. In contrast, Tregitopes are not found in other
antibody isotypes (IgE, IgA, and IgM). It is interesting to note
that IgGbut not IgMwas found to induce tolerance in seminal
studies of tolerance to haptens, performed byGolan andBorel
[23]. Tolerance induction to IgG Fc-conjugated antigens has
been extensively described by Scott et al. [24–26], among
others [27], who very clearly demonstrated that HLA class
II was involved [28] and that the effect did not require Fc
receptor binding [29], which supports our hypothesis that
tolerance is induced by the presence ofHLAclass II-restricted
Tregitopes. As described above, Tregitopes are also found in
IgG Fab, which can explain why Fab is as effective as IgG in
inducing Tregs [30].TheTregitope hypothesis is distinct from
the work of Anthony et al. [31], who suggest IVIG-induced
tolerance is mediated through sialylated Fc that initiate
an anti-inflammatory signaling cascade through the lectin
receptor SIGN-R1 or DC-SIGN. Tregitopes may, however,
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Figure 1: Potential IgG (and Tregitope) Mechanisms of Action.
From left to right, IVIG has been demonstrated to affect the cells
of the innate and adaptive immune system including NK cells,
macrophages, B cells, T cells, dendritic cells and other antigen
presenting cells.
explain the importance of binding to DC-SIGN, since that
surface molecule traffics bound antigens directly to the class
II processing and presentation pathway in dendritic cells.
2.3. Are Tregitopes the “Active Pharmaceutical Ingredient
(API)” of IVIG? The effects of IVIG have been attributed to a
wide array ofmechanisms (Figure 1). Additionalmechanisms
include the formation of immune complexes [32]; interaction
of sialylated Fc with a novel macrophage receptor DC-SIGN
[33]; blockade of Fc receptors leading to clearance of anti-
self antibodies [34]; immunomodulation via anti-idiotypic
interactions [35]; inhibition of complement-mediated tissue
damage [36]; direct modulation of cytokine expression by
leukocytes and endothelial cells; inhibition of superantigen-
mediated T-cell activation [31, 37, 38]; and induction of
nTregs [11]. IVIG has recently been shown to be associated
withmodulation of the regulatory T-cell axis, reduction of IL-
17 [39], and enhancement of the suppressive function of Tregs
[40]. In more recent studies by Massoud et al., the induction
of Tregs by IVIG was shown to be dependent on IgG binding
to a surface receptor called DCIR, followed by internaliza-
tion and processing [41]. Many of these observed effects
are consistent with the proposed Tregitope mechanism of
action, as Tregitopes are peptides that would result from IgG
internalization and processing, and have been associatedwith
expansion of existing Tregs and induction of iTregs. Internal-
ization of IgG (from IVIG), presentation of Tregitopes in the
context of MHC class II, and expansion of Tregitope-specific
Tregs would be consistent with recent observations that
administration of IVIG induces expansion of Tregs and IL-
10 secretion in vivo, in animals and in humans [9, 11, 42, 43].
3. Overview of Recent Tregitope Studies
3.1. Proposed Mechanism of Action. Since our original
description of Tregitopes in 2008, we have significantly
advanced our understanding of the Tregitope mechanism
of action, leading to our working hypotheses: (1) Tregitope
effects are contingent uponmajor histocompatibility complex
(MHC) class II-mediated presentation to a T cell by an
antigen-presenting cell (APC), (2) Tregs recognize Tregitopes
presented in the context ofMHCII and are activated, (3) these
activated Tregs produce IL-10 and interact with the APC to
reinforce the development of a tolerogenic phenotype, and (4)
these tolerogenic APCs and/or Tregs act on adjacent antigen-
specific effector T cells to suppress their effector responses
and induce antigen-specific Tregs. Published studies on Tre-
gitopes by our own group and our collaborators corroborate
the proposed mechanism, including in vivo studies, a few of
which are summarized in Section 4.
3.2. Comparison of Tregitopes to IVIG in EAE. In separate
in vivo and in vitro studies reviewed previously [4], we
collaborated with the laboratory of Khoury and Elyaman
to compare Tregitope peptide treatment to IVIG in the
EAE model of Multiple Sclerosis.The in vivo study evaluates
the capacity of IgG-derived Tregitope peptides to generate
antigen-specific adaptive tolerance induction to MOG35-55
epitopes. In that study, mice were presensitized by MOG
immunization. EAE disease was established and treated with
IVIG or human IgG Tregitope peptides 167 and 289 in saline
[4]. A tolerogenic effect of Tregitope peptides on immune
responses to the MOG35-55 epitopes was observed in vitro
and in vivo.These results are consistent with previous reports
by Legge et al. [44] who showed induction of Tregs by IgG
fusion proteins with multiple sclerosis antigens.
3.3. Tregitope Peptides Suppress CD4+ T-Cell Responses and
Are Not Immunogenic per se. In a recent paper, we demon-
strated that Tregitope peptides are not immunogenic in vivo
even when emulsified with potent adjuvants, such as IFA
or CFA [5]. Moreover, in vivo administration of Tregitope
peptides with IFA or CFA does not induce Th1 or Th2
cytokine expression under restimulation conditions in vitro.
We investigated tolerance induction by codelivering Tregi-
tope peptides with OVA using B cells. When B cells were
pulsed with OVA and Tregitope peptides and transferred into
na¨ıve mice, we found that cellular and humoral immune
responses to the OVA were suppressed as a result of their
ability to induce Tregs and the absence of immunogenicity
in the context of strong adjuvants [5].
3.4. Tregitope-Induced Tregs Also Modulate CD8+ T-Cell
Responses. Immune responses directed against viral capsid
proteins constitute a main safety concern in the use of
AAV as a gene transfer vector in humans. Using Tregitope
peptides, we showed that it is possible to modulate CD8+
T-cell responses to several viral antigens in vitro. Incuba-
tion of peripheral blood mononuclear cells with Tregitope
peptides and viral epitope peptides triggered proliferation
of CD4+CD25+FoxP3+ T cells that suppressed killing of
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target cells loaded with MHC class I antigens in an antigen-
specific fashion, through a mechanism that required cell-to-
cell contact. Expression of a construct encoding for the AAV
capsid structural protein fused to Tregitope peptides resulted
in reduction of CD8+ T-cell reactivity against the AAV capsid
following immunization with a capsid-expressing adenoviral
vector. This was accompanied by increased frequency of
CD4+CD25+FoxP3+ T cells in spleens and decreased inflam-
matory infiltrates in injected tissues.This study demonstrated
the feasibility of modulating CD8+ T-cell reactivity to an
antigen using Tregitopes.
4. Conclusion
4.1. Can Tregitope Peptides Replace IVIG? IVIG is a pooled
blood product from 10,000 or more donors. Many adverse
effects (AEs) associated with IVIG administration are mild
and transient, including headache, flushing, malaise, fever,
chills, fatigue, nausea, vomiting, diarrhea, blood pressure
changes, tachycardia, and anaphylactic reactions. Rare but
more severe AEs include acute renal failure, thromboem-
bolic events, skin-related effects including toxic epidermal
necrolysis, and aseptic meningitis [45]. Many of these effects
have been attributed to the targeting function of individual
antibodies in the polyclonal immunoglobulin mixture. In
general, however, IVIG is considered relatively safe. Thus,
the main incentives to seek alternatives are either economic
(to reduce the cost to patients and insurers) or to preserve
IVIG supply for patients with primary immunodeficiencies
who require the functional antibody component of IVIG to
protect against infections. Tregitopes may, in part, explain
the mechanism by which IVIG exerts its tolerogenic effect.
Where those effects are Treg-mediated, Tregitopes might
serve as an alternative IVIG for autoimmune conditions that
may be safer (due to the absence of the functioning antibody
component) and more effective.
If the induction of Tregs by IVIG can be attributed
to Tregitopes, then a number of autoimmune diseases for
which IVIG therapy is currently used, on-label and off, may
be appropriate targets for immunomodulatory formulations
that only contain Tregitope peptides. Two examples of dis-
ease in which IVIG is the predominant immunotherapy
include Chronic Inflammatory Demyelinating Polyneuropa-
thy (CIDP) and Multifocal Motor Neuropathy (MMN).
Introduction of Tregitope peptides as alternatives to IVIG
would also have a dramatic impact on the demand for
IVIG for immune modulation therapy [11, 43, 45]. IVIG also
acts rapidly and effectively in Immune Thrombocytopenic
Purpura (ITP), Kawasaki Syndrome (KS), polymyositis,
dermatomyositis, neurological syndromes such as Guillain-
Barre´ and CIDP, cases of severe steroid-dependent asthma,
and many others [46, 47]. Tregitope-peptide therapy may be
an attractive alternative to the systemic immune suppression
treatments that are sometimes used for these conditions.
4.2. Additional Tregitope Applications. Replacement of a
pooled-donor, blood-derived product for which the mech-
anism of action is not certain with a therapeutic product
for which the Active Pharmaceutical Ingredient (API) is
Figure 2: The broader relevance of Tregitopes is shown from left
to right (counter clockwise). Tregitopes may be incorporated into
protein drugs and monoclonal antibodies, to suppress antither-
apeutic protein immune responses. Removing Tregitopes from
autologous antigens would improve the ability of protein engineers
to develop effective antibodies for target (autologous) antigens,
and engineering Tregitope-depleted antibodies may improve the
delivery of vaccine antigens. As described in this paper, Tregitopes
may represent a new therapeutic option for autoimmune disease. In
addition, Tregitopes could be used to suppress autoimmune diseases
in companion animals.
precisely defined would represent a major step forward
for the field of autoimmune disease therapy. In addition,
since Tregitopes appear to be able to induce antigen-specific
tolerance (induced Tregs that are specific to coadministered
proteins), the possibility of tailoring the Tregitope therapy to
specific autoimmune diseases would represent an additional
advantage for clinical applications (Figure 2). One could
imagine allergen-specific treatments using combinations of
Tregitope peptides and allergen proteins or peptides, and
treatment for autoimmune diseases such as diabetes, which
would rely on coadministration of Tregitope peptides and
diabetes antigens. The idea of specifically generating MOG-
reactive Tregs is also particularly attractive for the therapy of
Multiple Sclerosis where, based on our data in the EAEmouse
model, we believe that Tregitope peptides induce antigen-
specific adaptive tolerance. Tregitopes may also have even
broader applications in protein therapeutics, animal health,
and blood factor or enzyme replacement therapy.
Treatment of many autoimmune diseases relies on
immunosuppressive therapy rather than on treatments
directed toward restoring a balance between effector and
regulatory immune responses. Given that Tregitope peptides
appear to induce adaptive tolerance in a mouse model, the
next consideration is to evaluate the optimal formulation and
determine the best time course of the tolerance induction,
in addition to measuring the duration of response, the dose
required, the safety and toxicity of the treatment (vis-a`-vis
other immune responses), and optimal formulation/route of
administration.Our preliminary studies suggest that adaptive
tolerance induction may be within reach, raising hopes that
we are on the right path for the development of an effective
immunotherapy-based approach to autoimmune disease.
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Glossary
Tregs: Regulatory T cells
Tregitopes: Treg epitopes (first described for IgG in 2008)
nTregs: Natural T regulatory cells
iTregs: Inducible T regulatory cells.
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